The Company allocates goodwill to reporting units within its Mobile Solutions, Industrial Solutions and Life Sciences segments. There were no dispositions or impairment charges recorded during the three and nine months ended April 30, 2026 and 2025. Goodwill is assessed for impairment annually during the third quarter of the fiscal year, or more frequently if events or changes in circumstances indicate the asset may be impaired. The Company performed its annual impairment assessment during the third quarter of fiscal 2026 and did not record any impairment as a result of this assessment.



	Mobile Solutions Segment		Industrial Solutions Segment		Life Sciences Segment		Total
Balance as of July 31, 2025	$	25.4	$	298.2	$	170.0	$	493.6



Foreign currency translation	0.2		2.8		2.8		5.8
Balance as of April 30, 2026	$	25.6	$	301.0	$	172.8	$	499.4


	April 30, 2026
	Weighted Amortizable Life (in Years)	Gross Carrying Amount		Accumulated Amortization		Net
Customer relationships	8.0	$	75.5	$	(45.6)	$	29.9

Trademarks	6.0	4.1		(2.5)		1.6
Technology and patents	16.0	81.5		(21.1)		60.4
Non-compete agreements	3.3	1.2		(0.8)		0.4
Total intangible assets		$	162.3	$	(70.0)	$	92.3


	July 31, 2025
	Weighted Amortizable Life (in Years)	Gross Carrying Amount		Accumulated Amortization		Net
Customer relationships	8.5	$	74.7	$	(43.7)	$	31.0

Trademarks	6.7	3.8		(2.0)		1.8
Technology and patents	16.6	82.9		(19.1)		63.8
Non-compete agreements	2.9	2.5		(1.7)		0.8
Total intangible assets		$	163.9	$	(66.5)	$	97.4

In the third quarter of fiscal 2025, the Company identified a triggering event related to certain asset groups and performed a valuation of certain long-lived intangible assets in accordance with ASC 360, Impairment and Disposal of Long-Lived Assets. The Company used a discounted cash flow analysis to estimate the fair value of each long-lived asset group. As a result of the valuation, the Company recorded $62.0 million of impairment expense related to intangible assets in the Company’s bioprocessing business within the Life Sciences segment. The impairment expense was included in Loss on impairment of intangible assets in the Condensed Consolidated Statements of Earnings. Of the impairment expense, $46.6 million was related to Univercells Technologies, reflecting lower-than-anticipated bioprocessing capital spending, particularly for early-stage assets, while drug development timelines are longer than previously anticipated. The remaining $15.4 million of impairment expense was related to Solaris as market demand for industrial bioreactors had significantly declined.

Intangible asset amortization expense was $2.5 million and $7.5 million for the three and nine months ended April 30, 2026, respectively, and was $3.4 million and $11.3 million for the three and nine months ended April 30, 2025, respectively. Amortization expense is included in selling, general and administrative expenses in the Condensed Consolidated Statements of Earnings.